Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
Prospective Comparison of PET Imaging with PSMA-Targeted
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The performance ofAsian journal of andrologyPooled it
- Trial
- Review
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.Radiology. Imaging cancer · 2025Article
- Prospective Head-to-Head Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Structured reporting in prostate cancer: the revolution of quality in nuclear medicine scan interpretation.European radiology · 2024Article
- Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.European urology · 2023Article
- Molecular imaging of bone metastasis.Journal of bone oncology · 2023Review
- Article
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.Biomedicines · 2022Review
- Review
- The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?Current opinion in urology · 2022Review
- A Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Translating a radiolabeled imaging agent to the clinic.Advanced drug delivery reviews · 2022Review
- Quantitative evaluation of PSMA PET imaging using a realistic anthropomorphic phantom and shell-less radioactive epoxy lesions.EJNMMI physics · 2022Article
- Enzymatic synthesis of fluorinated compounds.Applied microbiology and biotechnology · 2021Review
- Piflufolastat F 18: Diagnostic First Approval.Molecular diagnosis & therapy · 2021Review
- Article
- Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings onThe Journal of urology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases in prostate cancer (PCa) have important prognostic significance, and imaging modalities used for PCa staging should have high sensitivity for detecting such lesions. Prostate-specific membrane antigen (PSMA)-targeted PET radiotracers are promising new agents for imaging PCa. We undertook a head-to-head comparison of PSMA-targeted 2-(3-{1-carboxy-5-[(6-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.